Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer

Cancer Treatment Reviews
Eitan AmirMark Clemons

Abstract

In vitro studies have shown that lapatinib is most active in HER2 over-expressing tumors, but also has activity in cell lines over-expressing HER1. Consequently, clinical testing of lapatinib has been carried out in both HER2-positive and HER2-negative patients. Here we evaluate the clinical efficacy of lapatinib in HER2-positive and HER2-negative patients. A published data meta-analysis of randomized trials that evaluated the efficacy of combining lapatinib with chemo- or endocrine therapy in patients with metastatic breast cancer was undertaken. Hazard ratios (HR) were extracted for progression free survival (PFS) and overall survival, while odds ratios were extracted for disease stabilization, serious adverse events (SAEs) and need for discontinuation. Pooled estimates were computed using inverse-variance and random-effect modeling. Three randomized controlled trials with a total of 2264 patients met the inclusion criteria. Meta-analysis demonstrated the HR for PFS with lapatinib was 0.69 in patients with HER2-positive disease, while there was no improvement in PFS (HR=0.98, 95% CI 0.80-1.19) for treatment of HER2-negative breast cancer. Similarly, overall survival was improved in HER2-positive patients (HR 0.76, 95% CI 0.60...Continue Reading

References

Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John Mendelsohn, Jose Baselga
Feb 5, 2005·Breast Cancer Research and Treatment·Gunter von MinckwitzAndreas Schneeweiss
May 3, 2005·Nature Reviews. Cancer·Nancy E Hynes, Heidi A Lane
Jan 19, 2006·The Annals of Pharmacotherapy·Michael H Nelson, Christian R Dolder
Sep 1, 2006·Clinical Breast Cancer·Shanu ModiAndrew D Seidman
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Jan 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonNeil L Spector
Feb 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alberto Ocaña, Atanasio Pandiella
Feb 20, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J BursteinK L Blackwell
Mar 28, 2008·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
May 7, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry L GomezGeorge W Sledge
Oct 29, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMichael F Press
Sep 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JohnstonMark Pegram

❮ Previous
Next ❯

Citations

Jul 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W J Gradishar
May 17, 2014·Expert Opinion on Emerging Drugs·Ana LluchJose-Alejandro Perez-Fidalgo
Aug 1, 2016·Breast Cancer Research and Treatment·Anne F SchottGabriel N Hortobagyi
Aug 26, 2010·Expert Review of Anticancer Therapy·Hatem A Azim, Martine J Piccart
Mar 22, 2014·Molecular and Clinical Oncology·Shouji Shimoyama
Apr 10, 2018·Journal of Gastric Cancer·Hong Jun Kim, Sang Cheul Oh
Jan 27, 2016·World Journal of Gastroenterology : WJG·Suk-Young Lee, Sang Cheul Oh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer
Tanja Schneider-Merck, Martin Trepel
Expert Opinion on Drug Safety
Robyn J MacFarlane, Karen A Gelmon
© 2021 Meta ULC. All rights reserved